The development of potential antibody-based therapies for myeloma - sprookjes - yvandenbroek - TriplyDB

The development of potential antibody-based therapies for myeloma

The development of potential antibody-based therapies for myeloma

http://www.wikidata.org/entity/Q35788245

about

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?Targeted Therapies in Adult B-Cell Malignancies Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.RNA interference for multiple myeloma therapy: targeting signal transduction pathways.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.Emerging antibody-drug conjugates for treating lymphoid malignancies.Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.CD38 enhances the proliferation and inhibits the apoptosis of cervical cancer cells by affecting the mitochondria functions.A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.

P2860

Q26740359-D553D2A1-70FB-4883-86F0-F4A8F6FBB793 Q26783195-E9E3E4B7-C342-408E-AD44-28E7C21A22E1 Q26825644-E347F42F-4B59-4F30-A330-19279DADE31D Q37452241-CC80C7AA-A93F-4142-85DD-8E11984B6029 Q38534837-28A6890D-93AC-4E89-BE01-71084E7738BC Q38550480-5B1B5AA5-80BA-4CA8-B460-590AA566A991 Q38601582-886C3E47-9E56-487F-AE04-EEDC20265528 Q38632313-4C7C77C0-CB5A-495D-ABBA-478459BDA99C Q38755443-4FDA979A-3ADF-4222-9F05-A7A0578C8FED Q40575818-59D38CBB-FCA7-433E-AF1E-1FCB9919DE57 Q41770950-485F6B44-B571-4DBB-85A2-242D5A053F23 Q46360856-72A05B92-F6B2-4E7D-A22F-CF9A25B4791D Q47829053-1FFE5769-F7DD-4706-9F36-021F1A4B16A8

P2860

The development of potential antibody-based therapies for myeloma

http://www.wikidata.org/entity/Q35788245

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

The development of potential antibody-based therapies for myeloma

@ast

The development of potential antibody-based therapies for myeloma

@en

type

label

The development of potential antibody-based therapies for myeloma

@ast

The development of potential antibody-based therapies for myeloma

@en

prefLabel

The development of potential antibody-based therapies for myeloma

@ast

The development of potential antibody-based therapies for myeloma

@en

P1433

Q35788245-99D5C30E-6892-4731-9DC1-7E1634DAA526

P1476

Q35788245-1B263D16-83DC-46E0-A79D-EF559D692B33

P2093

Q35788245-15D0F953-F79E-4024-87E3-549E169B90EE

Q35788245-6D5588F2-8F81-42EF-BFE9-4FCEEBC3DECF

Q35788245-717D729D-97C3-4C1E-A53C-569A24502EFB

Q35788245-78D8C7F3-DD1B-4930-A84B-CB5C47186E67

Q35788245-BC1A3ED8-4EE8-4474-B2E5-7439E9E1DAC3

Q35788245-C9BA61E1-61D0-45D1-BB16-F2086C436F9C

P2860

Q35788245-0A333E6B-19D1-4E19-B5BA-022E32FE347F

Q35788245-0B76D51D-2039-4DFD-97DE-05BBB346EEAA

Q35788245-16F9ACFB-A469-488B-982B-3F453C9402B2

Q35788245-1A6BDD5E-AF05-44F7-A7B7-6BA5E10E62EE

Q35788245-1CAAFD8B-84DA-4AC7-AFE2-73C3A2036011

Q35788245-1CBB097A-4AE8-411A-9BE2-98DB46BABDF6

Q35788245-1D5A0F86-4F74-4831-B31A-558753102F4D

Q35788245-2271E263-EE3A-4F45-B4F8-FC57731A90E0

Q35788245-24D883DD-6754-489B-8D1C-4A8684914B53

Q35788245-27C3CBCE-63FA-4060-BDBA-D8FEB6BA9A75

P304

Q35788245-2A9F5C68-B5D5-486A-BADD-49B22C7029D4

P31

Q35788245-AD5189F9-8966-4F64-B67F-2F532D101C24

P356

Q35788245-66D0ED24-B2F9-4A6E-AB47-6BF254626A48

P433

Q35788245-21C28E14-6983-4C62-8506-A61182EDB568

P478

Q35788245-EFE7EBE4-8E42-402A-9D7D-50FDFA281201

P577

Q35788245-3ECB2C10-F877-4300-A478-C9A016F7A3BE

P5875

Q35788245-7DFC4C6B-6450-49BF-AA59-B0E7A13EEC8B

P698

Q35788245-E1DD090B-E6EE-427E-B586-DBAFF3272E49

P932

Q35788245-4F4F18F7-D596-46CD-A340-1BA4023C7DC6

P356

J.BLRE.2014.09.011

P1433

P1476

The development of potential antibody-based therapies for myeloma

@en

P2093

Bin Liu

http://www.w3.org/2001/XMLSchema#string

Christopher R Behrens

http://www.w3.org/2001/XMLSchema#string

Daniel W Sherbenou

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Wolf

http://www.w3.org/2001/XMLSchema#string

Thomas G Martin

http://www.w3.org/2001/XMLSchema#string

Yang Su

http://www.w3.org/2001/XMLSchema#string

P2860

A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion

Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease

Identification of a family of Fc receptor homologs with preferential B cell expression

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

B lymphocytes express and lose syndecan at specific stages of differentiation

Characterization of clonogenic multiple myeloma cells

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

P304

81-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BLRE.2014.09.011

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266625083

http://www.w3.org/2001/XMLSchema#string

P698

25294123

http://www.w3.org/2001/XMLSchema#string

P932

4482758

http://www.w3.org/2001/XMLSchema#string